Litigation Details for Helsinn Healthcare SA v. Mylan Institutional LLC (D. Del. 2014)

Helsinn Healthcare SA v. Mylan Institutional LLC (D. Del. 2014)

Docket	1:14-cv-00709	Date Filed	2014-06-04
Court	District Court, D. Delaware	Date Terminated	2015-10-05
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	7,947,724; 7,947,725; 7,960,424; 8,598,219; 8,729,094
Link to Docket	External link to docket

Details for Helsinn Healthcare SA v. Mylan Institutional LLC (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-06-04				External link to document

Helsinn Healthcare SA v. Mylan Institutional LLC, 1:14-cv-00709: Litigation Summary and Patent Analysis

Last updated: August 27, 2026

Helsinn Healthcare SA sued Mylan Institutional LLC in the District of Delaware after Mylan submitted an ANDA seeking approval to market a generic version of Aloxi, Helsinn’s palonosetron hydrochloride injection. The dispute involved Orange Book-listed patents covering the intravenous antiemetic product and its dosing regimen. The case was part of a broader generic-entry challenge to Aloxi and did not produce the controlling on-sale-bar ruling later issued in the separate Helsinn v. Teva litigation.

What was Helsinn Healthcare SA v. Mylan Institutional LLC about?

The case concerned Mylan’s proposed generic palonosetron hydrochloride injection, an intravenous 5-HT3 receptor antagonist used to prevent chemotherapy-induced nausea and vomiting.

Item	Information
Court	U.S. District Court for the District of Delaware
Case number	1:14-cv-00709
Plaintiff	Helsinn Healthcare SA
U.S. commercial affiliate	Helsinn Therapeutics (U.S.), Inc.
Defendant	Mylan Institutional LLC
Product	Generic palonosetron hydrochloride injection
Reference product	Aloxi injection
Regulatory pathway	ANDA with Paragraph IV certifications
Filing year	2014
Case type	Hatch-Waxman patent infringement litigation
Result	Resolved without a reported merits opinion or public trial judgment

The complaint followed Mylan’s Paragraph IV certifications asserting that the relevant Aloxi patents were invalid, unenforceable, or would not be infringed by Mylan’s proposed product. Under 21 U.S.C. § 355(j)(5)(B)(iii), filing the patent challenge created a statutory basis for Helsinn to sue within 45 days and triggered an FDA approval stay.

What patents protected Aloxi and palonosetron injection?

The Aloxi patent estate centered on patents covering palonosetron formulations, dosage strengths, and methods of preventing chemotherapy-induced nausea and vomiting.

The principal patent family included:

Patent	General subject matter	Relevance to Aloxi litigation
U.S. Patent No. 7,947,724	Palonosetron formulation and use claims	Core Orange Book-listed patent
U.S. Patent No. 8,598,219	Related palonosetron formulation and treatment claims	Asserted or implicated in generic challenges
U.S. Patent No. 8,729,094	Continuation-family claims relating to palonosetron treatment	Part of the broader Aloxi estate
U.S. Patent No. 9,066,906	Later-issued continuation claims	Relevant to continuing generic-entry disputes

The claims generally targeted the use of palonosetron hydrochloride at low intravenous doses, including the 0.25 mg dose used in Aloxi, and formulations designed for parenteral administration. The patent family had a common priority lineage and was prosecuted through continuation applications.

The commercially important distinction was between:

1. Product or formulation claims, which could block approval of a generic injection matching Aloxi’s composition; and
2. Method-of-use claims, which could create narrower infringement exposure depending on the generic label and the uses carved out by the ANDA applicant.

What was Mylan’s Paragraph IV challenge?

Mylan’s ANDA challenge placed the Aloxi patent estate directly into the Hatch-Waxman litigation process. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or not infringed by the proposed generic product.

Mylan’s likely exposure fell into two categories:

• Formulation infringement: Whether the proposed palonosetron injection fell within the structural and concentration limitations of the asserted claims.
• Method-of-use infringement: Whether the proposed labeling directed use of palonosetron for indications covered by Helsinn’s patents.

A Paragraph IV certification does not itself invalidate a patent. It creates a litigation pathway. Helsinn had to prove infringement, while Mylan could attack validity based on anticipation, obviousness, written description, enablement, and the statutory on-sale bar.

How did the case proceed procedurally?

The Delaware case was filed in 2014 after Mylan’s ANDA activity. The publicly reported docket does not contain a final claim-construction opinion, trial verdict, or post-trial judgment resolving the asserted claims against Mylan.

The case therefore appears to have ended through a negotiated resolution or docket disposition rather than a published merits decision. The principal commercial consequence was the resolution of Helsinn’s claims against Mylan, not a judicial determination that the Aloxi patents were valid or infringed by Mylan.

Litigation milestone	Assessment
ANDA challenge	Mylan submitted Paragraph IV certifications
Complaint	Helsinn filed in the District of Delaware in 2014
Patent issues	Validity, infringement, and enforceability of Aloxi-related patents
Claim construction	No reported dispositive construction opinion located
Trial	No reported trial verdict
Settlement	Case resolved without publicly reported material terms
Final merits ruling	None reported in the Delaware action

A settlement in a Hatch-Waxman case can establish a negotiated generic-entry date without resolving the underlying validity of the patents. Unless the agreement is disclosed through a Federal Trade Commission filing, SEC disclosure, court order, or later regulatory event, the economic terms and launch date may remain confidential.

What was the relationship between this case and Helsinn v. Teva?

The Delaware Mylan case should be separated from the Supreme Court’s decision in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc.

The Teva litigation involved the same general Aloxi patent family and a dispute over whether Helsinn’s confidential 2001 agreements with a potential commercial partner triggered the pre-America Invents Act on-sale bar. The U.S. Supreme Court held that a sale or offer for sale can qualify as prior art under 35 U.S.C. § 102(a)(1) even when the transaction’s terms and existence are subject to confidentiality restrictions. Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 586 U.S. 123 (2019).

That ruling addressed the legal meaning of “on sale.” It did not decide the Mylan case and did not automatically invalidate every Aloxi patent. Its significance for the Mylan dispute was indirect:

• Mylan could have used the same transaction history in a validity challenge if the relevant patents and claim dates overlapped.
• The Supreme Court ruling strengthened the legal availability of secret-sale evidence as prior art.
• The impact depended on the specific asserted claims, priority dates, and evidentiary record in the Mylan docket.

What was the FDA and Orange Book status of Aloxi?

Aloxi was approved by the FDA as palonosetron hydrochloride injection for prevention of acute nausea and vomiting associated with moderately emetogenic chemotherapy and for prevention of nausea and vomiting associated with highly emetogenic chemotherapy in adults. It also received approval for prevention of postoperative nausea and vomiting in adults. FDA labeling identifies the active ingredient as palonosetron hydrochloride. [FDA, 2024a]

The Orange Book listed patents for the approved Aloxi product. Those listings provided the basis for the Paragraph IV dispute. The relevant patent family had nominal terms expiring around the mid-2020s, subject to patent-term adjustment and any regulatory exclusivity periods.

Regulatory issue	Analysis
Reference drug	Aloxi
Active ingredient	Palonosetron hydrochloride
Dosage form	Intravenous injection
FDA pathway for Mylan	ANDA
Patent certification	Paragraph IV
Biosimilar pathway	Not applicable
Main barrier to entry	Small-molecule patent and regulatory exclusivity
Orange Book significance	Listed patents could trigger a 30-month approval stay

Aloxi is a small-molecule drug, not a biologic. Biosimilar litigation under the Biologics Price Competition and Innovation Act therefore was not relevant. Generic applicants used the ANDA pathway rather than a 351(k) biosimilar application.

When did Aloxi lose exclusivity?

Aloxi’s practical exclusivity depended on three separate elements:

1. FDA regulatory exclusivity;
2. The enforceable term of the Orange Book-listed patents; and
3. The outcome or settlement of Paragraph IV litigation.

The key Aloxi patents were generally understood to have expiration dates in the 2024-2026 period, depending on the specific patent and patent-term adjustment. By the time those patents expired or became commercially ineffective through settlements, the principal barrier to generic palonosetron injection was removed.

Patent expiry did not necessarily produce immediate generic competition. A generic applicant also needed final ANDA approval, manufacturing capacity, commercial inventory, and a label that complied with any method-of-use restrictions.

What generic launch risks did Mylan present?

Mylan presented a conventional first-wave generic threat to Helsinn’s Aloxi revenue. The commercial risks were significant because palonosetron injection was a hospital and oncology product with relatively concentrated prescribing channels.

The main scenarios were:

Launch after patent expiry

Mylan could enter after the relevant patents expired, subject to FDA approval. This was the lowest litigation-risk scenario and the most predictable for Helsinn.

Launch under a settlement date

If the parties settled, Mylan could receive a licensed entry date before patent expiration. Such settlements often include restrictions on launch timing, authorized-generic rights, supply arrangements, or manufacturing conditions.

At-risk launch

Mylan could launch before final resolution if it believed the patents were invalid or not infringed. An at-risk launch would expose Mylan to damages, an injunction request, and potential treble damages for willful infringement. The public docket does not show that Mylan completed an at-risk launch tied to this case.

Carved-out label

Mylan could seek approval with a “section viii” label carve-out for uses covered by method-of-use patents. This approach would not avoid formulation patents and would depend on whether the remaining label still encouraged infringing use.

How strong was the Helsinn patent estate?

The estate had meaningful structural strength because it used several continuation patents and combined formulation and method-of-use claims. That structure increased the cost of a generic challenge and allowed Helsinn to assert different claim categories against different ANDA products.

Its vulnerabilities were also material:

• The patents shared an early commercial-development history.
• The 2001 agreements later examined in the Teva litigation created an on-sale-bar issue.
• Continuation claims could face written-description and obviousness attacks.
• Method-of-use claims were vulnerable to label carve-outs.
• Patent expiration was close enough to the litigation period to reduce the economic value of prolonged enforcement.

The estate’s strength was therefore commercial and procedural rather than absolute. It could delay generic approval and support settlement leverage, but the on-sale-bar dispute created a substantial validity risk for at least part of the family.

What litigation affects Aloxi generic entry?

The most important related case is:

Case	Court	Issue	Outcome
Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc.	U.S. Supreme Court	Whether a confidential commercial sale can trigger the on-sale bar	Supreme Court held that confidentiality does not remove a sale from § 102(a)(1)
Helsinn Healthcare S.A. v. Dr. Reddy’s Laboratories Ltd.	Federal courts	Validity and infringement of Aloxi-related patents	Part of the broader generic challenge landscape
Helsinn Healthcare SA v. Mylan Institutional LLC	D. Del.	Mylan’s ANDA and Paragraph IV certifications	Resolved without a reported merits judgment

The Teva decision is the controlling legal authority on the secret-sale issue. It is not a ruling on Mylan’s infringement or on the ultimate validity of every patent asserted against Mylan.

Were there licensing deals or settlement agreements?

The Mylan docket does not provide a reported, detailed settlement opinion describing the parties’ commercial terms. The case’s resolution therefore should not be treated as a judicial finding that Mylan infringed valid patents.

Possible settlement components in this type of case include:

• A fixed generic-entry date;
• A license to the relevant patent family;
• Restrictions on launch before patent expiry;
• An authorized-generic arrangement;
• Supply or manufacturing terms; and
• Mutual releases.

None of those terms should be attributed to this case without a public agreement or regulatory filing. The reliable conclusion is that the litigation ended without a reported public merits decision.

What was the revenue exposure from Mylan’s challenge?

Aloxi revenue was exposed to generic substitution because the product was administered in hospitals, oncology clinics, and outpatient facilities where generic injectable competition can quickly affect contracting and reimbursement.

The financial impact depended on:

• Mylan’s approval and launch timing;
• The number of competing ANDA applicants;
• Whether Mylan launched as a sole first entrant or in a crowded market;
• Hospital purchasing contracts;
• The availability of an authorized generic;
• The scope of any settlement license; and
• The enforceability of the asserted patents after the Teva on-sale-bar ruling.

The strongest revenue-protection scenario was delayed generic entry through patent enforcement or a settlement license. The weakest scenario was an early launch following a successful validity challenge, especially if multiple generic manufacturers entered simultaneously.

Key Takeaways

• Helsinn sued Mylan in 2014 over a Paragraph IV challenge to generic palonosetron hydrochloride injection.
• The dispute involved the Aloxi patent family, including U.S. Patent Nos. 7,947,724 and 8,598,219 and related continuation patents.
• The case was filed in the District of Delaware under No. 1:14-cv-00709.
• No reported final merits opinion, trial verdict, or claim-construction decision resolved the Mylan case.
• The case was distinct from the Supreme Court’s Helsinn v. Teva decision, which held that confidential sales can trigger the patent on-sale bar.
• Biosimilar risk was irrelevant because Aloxi is a small-molecule drug regulated through the ANDA pathway.
• Generic-entry risk depended on patent expiry, settlement timing, label carve-outs, FDA approval, and the commercial viability of injectable palonosetron.
• The Aloxi patent estate had meaningful continuation and formulation coverage but faced material validity risk from the commercial-sale history examined in the Teva litigation.

FAQs About Helsinn Healthcare SA v. Mylan Institutional LLC

Did Mylan receive FDA approval for generic Aloxi?

Mylan’s litigation arose from an ANDA and Paragraph IV certifications. The Delaware docket does not establish, by itself, the date or scope of any final FDA approval or commercial launch.

Was the Helsinn-Mylan case dismissed with prejudice?

The public litigation record reflects resolution without a reported merits judgment. The operative dismissal language and any confidential settlement terms should not be treated as a judicial validity determination.

Did the Supreme Court’s Helsinn decision invalidate the patents asserted against Mylan?

No. The Supreme Court decided the statutory on-sale-bar question in the Teva litigation. It did not enter judgment against Mylan or invalidate every Aloxi patent.

Could Mylan use a section viii label carve-out?

Potentially. A carve-out could address method-of-use claims, but it would not necessarily avoid infringement of formulation or product claims covering the generic injection itself.

Are palonosetron patents still a major barrier to generic entry?

The principal Aloxi patent terms were approaching or reaching expiration in the mid-2020s. Current entry risk depends more heavily on FDA approval status, remaining listed patents, manufacturing economics, and the number of approved ANDA applicants.

References

1. Food and Drug Administration. (2024a). Aloxi (palonosetron hydrochloride) injection prescribing information. U.S. Department of Health and Human Services.

2. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

3. Helsinn Healthcare SA v. Mylan Institutional LLC, No. 1:14-cv-00709, U.S. District Court for the District of Delaware.

4. Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 586 U.S. 123 (2019).

5. Leahy-Smith America Invents Act, Pub. L. No. 112-29, 125 Stat. 284 (2011).

6. 21 U.S.C. § 355(j).

7. 35 U.S.C. § 102(a)(1).